肺和肠道微生物组：囊性纤维化需要考虑什么？
The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis?
机构信息
Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France; Unité de Bactériologie, Pôle de Biologie-Pathologie, Hôpital La Cavale Blanche, CHRU de Brest, Brest, France.
Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
出版信息
J Cyst Fibros. 2019 Jan;18(1):13-21. doi: 10.1016/j.jcf.2018.11.003. Epub 2018 Nov 25.
The 15th European Cystic Fibrosis Society (ECFS) Basic Science pre-conference Symposium focused on the topic of the microbiome, asking the question "The lung and gut microbiome: what has to be considered for cystic fibrosis (CF)?" This review gives an overview of the main points raised during the symposium, which dealt with the technical considerations, pathophysiology and clinical implications of the microbiome in CF.
第 15 届欧洲囊性纤维化学会（ECFS）基础科学会前研讨会的主题聚焦于微生物组，提出了“肺部和肠道微生物组：囊性纤维化（CF）需要考虑哪些因素？”这篇综述概述了研讨会提出的主要观点，涉及 CF 中微生物组的技术考虑、病理生理学和临床意义。
Zotero 插件